Edgewise Therapeutics, Inc.
EWTX
$13.45
$0.423.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -133.81M | -124.29M | -115.88M | -105.85M | -100.16M |
| Total Depreciation and Amortization | 2.29M | 2.19M | 2.09M | 2.02M | 1.73M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.17M | 10.01M | 8.56M | 8.00M | 8.04M |
| Change in Net Operating Assets | 10.33M | 3.19M | 1.65M | -1.89M | -1.56M |
| Cash from Operations | -109.03M | -108.90M | -103.59M | -97.72M | -91.95M |
| Capital Expenditure | -1.31M | -1.20M | -1.14M | -1.67M | -5.75M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -183.34M | -177.40M | -179.40M | -212.79M | 108.63M |
| Cash from Investing | -184.66M | -178.60M | -180.54M | -214.46M | 102.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 249.52M | 299.56M | 296.01M | 294.38M | 53.33M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -262.00K | -213.00K | -213.00K | -165.00K | -165.00K |
| Cash from Financing | 249.25M | 299.35M | 295.80M | 294.22M | 53.17M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -44.43M | 11.85M | 11.68M | -17.97M | 64.10M |